Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 6807-83-6
2. (-)-maackiain-3-o-glucoside
3. Chebi:9714
4. Trifolrhizin
5. (2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-[[(1r,12r)-5,7,11,19-tetraoxapentacyclo[10.8.0.02,10.04,8.013,18]icosa-2,4(8),9,13(18),14,16-hexaen-16-yl]oxy]oxane-3,4,5-triol
6. (-)-maackiain 3-o-glucoside
7. Sophojaponicin B2
8. Chembl454878
9. Mfcd00238700
10. N1959
11. Acon1_002295
12. Dtxsid70987516
13. Hy-n0616
14. Zinc4098749
15. S9425
16. Akos030632879
17. Ccg-269193
18. Ncgc00169980-01
19. Ncgc00169980-03
20. Trifolirhizin, >=95% (lc/ms-elsd)
21. Beta-d-glucopyranoside, 6a,12a-dihydro-6h-(1,3)dioxolo(5,6)benzofuro(3,2-c)(1)benzopyran-3-yl, (6ar-cis)-
22. Trifolirhizin;(-)-maackiain-3-o-glucoside
23. Cs-0009612
24. 807t836
25. Q-100766
26. Brd-k43094903-001-01-3
27. Q27108480
28. (2s,3r,4s,5s,6r)-2-(((6ar,12ar)-6a,12a-dihydro-6h-[1,3]dioxolo[4',5':5,6]benzofuro[3,2-c]chromen-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
29. Ncgc00169980-03_c22h22o10_beta-d-glucopyranoside, (6ar,12ar)-6a,12a-dihydro-6h-[1,3]dioxolo[5,6]benzofuro[3,2-c][1]benzopyran-3-yl
| Molecular Weight | 446.4 g/mol |
|---|---|
| Molecular Formula | C22H22O10 |
| XLogP3 | 0.6 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 3 |
| Exact Mass | 446.12129689 g/mol |
| Monoisotopic Mass | 446.12129689 g/mol |
| Topological Polar Surface Area | 136 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 679 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 7 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Trifolirhizin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Trifolirhizin, including repackagers and relabelers. The FDA regulates Trifolirhizin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Trifolirhizin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Trifolirhizin supplier is an individual or a company that provides Trifolirhizin active pharmaceutical ingredient (API) or Trifolirhizin finished formulations upon request. The Trifolirhizin suppliers may include Trifolirhizin API manufacturers, exporters, distributors and traders.
Trifolirhizin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Trifolirhizin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Trifolirhizin GMP manufacturer or Trifolirhizin GMP API supplier for your needs.
A Trifolirhizin CoA (Certificate of Analysis) is a formal document that attests to Trifolirhizin's compliance with Trifolirhizin specifications and serves as a tool for batch-level quality control.
Trifolirhizin CoA mostly includes findings from lab analyses of a specific batch. For each Trifolirhizin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Trifolirhizin may be tested according to a variety of international standards, such as European Pharmacopoeia (Trifolirhizin EP), Trifolirhizin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Trifolirhizin USP).
LOOKING FOR A SUPPLIER?
